WHO ICTRP trial
A study of investigational medicinal product AL101 in adults with breast cancer
EUCTR2020-001979-33-GB · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2020-001979-33-GB |
|---|---|
| Public title | A study of investigational medicinal product AL101 in adults with breast cancer |
| Scientific title | A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer - TENACITY |
| Primary sponsor | Ayala Pharmaceuticals, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;France;Spain;Belgium;Israel;Netherlands;United Kingdom |
| Conditions | Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified… |
| Interventions | Product Code: AL101 Pharmaceutical Form: Solution for infusion INN or Proposed INN: - CAS Number: 1401066-79-2 Current Sponsor code: AL101 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number… |
| Registration date | Sep 10, 2020 |
| Target size | 73 |
| Secondary IDs | AL-TNBC-01 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: